N/A Completed N=579

Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation

Liver disease

Source: ClinicalTrials.gov NCT02084160 ↗

Enrolled (actual)

579

Serious AEs

—

Results posted

Sep 2019

Primary outcomePrimary: Hepatic Decompensation Event — 324 number of events

Summary

The objectives of this study are: * To evaluate the ability of the Methacetin Breath Test (MBT) to detect hepatic decompensation events * To evaluate the relationship between liver Biopsy and clinical outcome and show that the MBT has a better predictive ability of clinical outcome than liver biopsy. * To evaluate the ability of the MBT to predict each of the individual liver related complications.

Outcome Measures

Outcome	Result	p-value
PRIMARY Hepatic Decompensation Event	324	—

Eligibility Criteria

Inclusion Criteria

All subjects that aere enrolled in the previous Exalenz trial HIS-EX-408 or PLT-BID-1108

Exclusion Criteria

None

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02084160). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.